Alan Hoffmann Net Worth

The estimated Net Worth of Alan Hoffmann is at least $7.38 Tisíc dollars as of 22 October 2020. Mr. Hoffmann owns over 19,230 units of Perspective Therapeutics Inc stock worth over $7,384 and over the last 9 years he sold ISR stock worth over $0. In addition, he makes $0 as Independent Director at Perspective Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hoffmann ISR stock SEC Form 4 insiders trading

Alan has made over 3 trades of the Perspective Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 19,230 units of ISR stock worth $10,000 on 22 October 2020.

The largest trade he's ever made was buying 25,000 units of Perspective Therapeutics Inc stock on 20 November 2018 worth over $10,000. On average, Alan trades about 4,941 units every 109 days since 2016. As of 22 October 2020 he still owns at least 19,230 units of Perspective Therapeutics Inc stock.

You can see the complete history of Mr. Hoffmann stock trades at the bottom of the page.

Alan Hoffmann biography

Alan Hoffmann is Independent Director of IsoRay, Inc., since January 2016. He is the owner of Alan Hoffmann, CPA, PC, a certified public accounting firm he founded in 1996. The firm performs audits and reviews of private companies. In addition, Mr. Hoffmann currently serves as CFO for Cognitive Research Corporation, a privately-held, full-service contract research organization that specializes in central nervous system product development for pharmaceutical, nutraceutical, biotechnology and medical device companies. In 2011, he served as CFO for an international manufacturing company, Kinematics Manufacturing, Inc. His prior employment included Price Waterhouse from 1985-1989, and local firms in Arizona from 1989 to 1996, where he held multiple positions including Senior Tax Analyst, and Tax Manager. After receiving his undergraduate accounting degree with honors from the University of Wisconsin-Milwaukee in 1985, he became a Certified Public Accountant in 1989. He also served in the United States Marine Corps and was honorably discharged in 1985. He brings over 27 years of public accounting experience to the Company and the Board. Mr. Hoffmann brings to the Board his experience as a public accountant and understanding of oversight and review of financial statements prepared by the Chief Financial Officer.

How old is Alan Hoffmann?

Alan Hoffmann is 58, he's been the Independent Director of Perspective Therapeutics Inc since 2016. There are 2 older and 14 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.

What's Alan Hoffmann's mailing address?

Alan's mailing address filed with the SEC is 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX, AZ, 85032.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy a Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.

What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Complete history of Mr. Hoffmann stock trades at Perspective Therapeutics Inc

Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lori Woods,
  Chief Executive Officer, Director
• Lori A. Holmes-Woods,
  CEO & Director
• Michael Krachon,
  Executive Vice President of Sales and Marketing
• William Cavanagh,
  Chief Research and Development Officer
• Michael L. Krachon,
  Exec. VP of Sales & Marketing
• Jennifer Streeter,
  COO & VP of HR
• William A. Cavanagh III,
  Chief R&D Officer
• Krista Cline,
  Senior Director of Operations, Corporate Secretary
• Philip Vitale,
  Independent Director
• Alan Hoffmann,
  Independent Director
• Jonathan Hunt,
  Chief Financial Officer, Co-Principal Financial Officer
• Mark Austin,
  Controller, Co-Principal Financial and Principal Accounting Officer
• Jennifer Streeter,
  Chief Operating Officer, Vice President of Human Resources
• Michael McCormick,
  Independent Chairman of the Board
• Krista Cline,
  Sr. Director of Operations & Corp. Sec.
• Mark J. Austin CPA,
  VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
• Jonathan R. Hunt,
  CFO & Co-Principal Financial Officer
• Frank Morich,
  Director
• Brien Ragle,
  Controller
• Dwight William Babcock,
  CEO
• Matthew Branson,
  Principal Fin & Acct Officer
• Robert F Iii Williamson,
  Director
• Thomas C Lavoy,
  Director
• Albert Louis Smith,
  Director
• Roger Girard,
  CEO/President
• Robert R Kauffman,
  Director
• Fredric Swindler,
  Vice President
• David Swanberg,
  EVP Operations & Secretary
• Stephen Boatwright,
  Director